Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Downgrades Verona Pharma to Neutral, Raises Price Target to $107

Author: Benzinga Newsdesk | July 14, 2025 06:30am
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Neutral and raises the price target from $90 to $107.

Posted In: VRNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist